Cara Therapeutics (CARA) : Traders are bullish on Cara Therapeutics (CARA) as it has outperformed the S&P 500 by a wide margin of 57.8% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 13.73%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 13.92% in the last 1 week, and is up 56.96% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 24.24% and the 50-Day Moving Average is 34.06%.The 200 Day SMA reached 14.54%
Cara Therapeutics (NASDAQ:CARA): After opening at $8.15, the stock dipped to an intraday low of $7.83 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $8.4 and the buying power remained strong till the end. The stock closed at $8.35 for the day, a gain of 1.95% for the day session. The total traded volume was 1,589,956. The stocks close on the previous trading day was $8.35.
Cara Therapeutics (CARA) : The most positive equity analysts on Cara Therapeutics (CARA) expects the shares to touch $24, whereas, the least positive believes that the stock will trade at $16 in the short term. The company is covered by 4 Wall Street Brokerage Firms. The average price target for shares are $20.5 with an expected fluctuation of $4.12 from the mean.
Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. The Company is engaged in developing product candidates that focus on the bodys peripheral nervous system. Its product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845 for acute and chronic pain, and CR701 for neuropathic and inflammatory pain. CR845 is a peripherally-acting kappa opioid receptor agonist for the treatment of both acute and chronic pain. I.V. CR845 is an injectable version of its peripheral kappa opioid receptor agonist, which is designed to provide pain relief without stimulating mu opioid receptors. CR701 is a peripherally-restricted, mixed-CB1/CB2 receptor agonist that interacts with these cannabinoid receptor subtypes, with no off-target activities.